Notice & News | SILLAJEN

Notice & News

Targeting, Attacking, and Eradicating Cancers®

Notice & News

게시판

Total 25. ˙ 2/3 Page

15 Regeneron and SillaJen Announce Immuno-Oncology Clinical Study Agreement for Combination Treatment in Kidney Cancer 2017-05-08
14 Enrollment of the First European Patient in Multinational Phase 3 Trial 2017-04-24
13 Issuance of Two Australian Patents 2017-03-02
12 SillaJen IR Letter (2017.01) 2017-01-03
11 SillaJen to use IPO proceeds to fund clinical trial of liver cancer drug in 11 countries 2016-11-14
10 SillaJen Announces Commercial Manufacturing Agreement with ABL Europe For Lead Oncolytic Virus, Pexa-Vec 2016-05-17
9 SillaJen Enrolls First U.S. Patient in Multinational Phase 3 Trial for Pexa-Vec in Advanced Liver Cancer 2016-03-29
8 SillaJen Announces First Patient Randomized in Multinational Phase 3 Trial for Pexa-Vec in Advanced Liver Cancer 2016-01-06
7 SillaJen Presents Data Demonstrating Pexa-Vec Synergy with Angiogenesis Inhibitors: A Collaboration with University of California, San Francisco 2015-06-29
6 SillaJen Announces Agreement with the FDA for a Special Protocol Assessment for Upcoming Phase 3 Pexa-Vec Trial in Advanced Liver Cancer 2015-04-20